Anesthesia Drugs Market Analysis

Report ID: 5842
Published Date: Sep 16, 2025
Report Format: PDF, PPT

Buy Now

Anesthesia Drugs Market Segmentation:

Drugs

The propofol segment is estimated to hold 36% share of the global anesthesia drugs market by 2035. Among the most widely used general anesthetics for surgeries, propofol is also utilized as a sedative in the intensive care unit (ICU) for patients in critical care, particularly those with COVID-19. It is employed in the beginning and continuation of general anesthesia, procedural sedation, etc.

The use of Fresenius Propoven 2% emulsion to sustain sedation in COVID-19 patients in need of mechanical breathing was approved by the US Food and Drug Administration in June 2020. Its lipophilic nature and quick onset of action with little adverse effects make it a popular choice for surgical procedures. Anesthesiologists frequently employ propofol, together with anxiolytics and analgesics, to promote sleep while allowing patients to continue breathing on their own at lower dosages. Additionally, refractory-grade epileptics can be treated with propofol. In adult patients, propofol is often used in ventilation-based sedation procedures when other drugs are not working. Furthermore, in the intensive care unit (ICU), propofol is utilized as a primary anesthetic to provide patients with deep drowsiness while they are hooked up to ventilators.

Application

Based on application, the general surgeries segment in the anesthesia drugs market is predicted to hold the largest revenue share of about 30% during the projection period. Over the projected period, a large growth in the market will be seen. The market is being pushed by the number of surgeries rising, the population being older and having more chronic illnesses, and improvements in anesthesia technology. According to data from the American Society of Plastic Surgeons (ASPS), 16.3 million cosmetic minimally invasive treatments and around 1.8 million cosmetic surgical operations were carried out in the US in 2019.

Our in-depth analysis of the anesthesia drugs market includes the following segments:

Drug Class	General Anesthetics Local Anesthetics
Application	Plastic Surgeries Cosmetic Surgeries General Surgeries Dental Surgeries Gynaecology Surgeries
Drugs	Propofol Sevoflurane Dexmedetomidine Desflurane Remifentanil Midazolam
End User	Hospitals Ambulatory Surgical Centers Specialty Clinics

Browse key industry insights with market data tables & charts from the report:

Anesthesia Drugs Market Size, Share, Trends & Industry Forecast 2035

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of anesthesia drugs is estimated at USD 5.41 billion.

The global anesthesia drugs market size crossed USD 5.24 billion in 2025 and is likely to expand at a CAGR of more than 3.5%, surpassing USD 7.39 billion revenue by 2035.

North America anesthesia drugs market is growing steadily with a 33% share by 2035, driven by the rising incidence of chronic illnesses and cancer cases requiring surgical treatment.

Key players in the market include Hikma Pharmaceuticals Plc, Abbott Laboratories, GE Healthcare, Aspen Pharmacare Holdings Limited, Avet Pharmaceuticals, Inc., Par Pharmaceuticals, Teva Pharmaceuticals, Novartis AG, Heron Pharmaceutical, Inc., Piramal Enterprises Limited.